Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for lung cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
: about 60% of NSCLCs are adenocarcinoma. Former or current smoking is often a causal factor in all forms of lungcancer. However, nonsmokers with lungcancer frequently have adenocarcinoma. This type of cancer is usually found on the outer parts of the lung. People with adenocarcinoma tend to have better survival than people with other types of lungcancer • Squamous cell (epidermoid) carcinoma: 25% to 30% of all NSCLCs are squamous cell carcinomas. Squamous cells are flat cells that line the inside (...) • Other subtypes: Less common NSCLC subtypes include adenosquamous carcinoma and sarcomatoid carcinoma The progression of cancer is divided into four stages; a higher number signifies more extensive disease. In stage 1, the cancer is confined to the original site within the lung and there is no sign of spread to lymph nodes (N0) or elsewhere (M0). In stage 2, the cancer has spread to lymph nodes within the lung (N1). In stage 3, the cancer has spread to lymph nodes in the middle of the chest
(Lorviqua ® ) is accepted for use within NHSScotland on an interim basis subject to ongoing evaluation and future reassessment. Indication under review: as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lungcancer (NSCLC) whose disease has progressed after: ? alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or ? crizotinib and at least one other ALK TKI In the relevant subgroup of a non-comparative (...) Scottish Medicines Consortium www.scottishmedicines.org.uk 2 Indication As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)- positive advanced non-small cell lungcancer (NSCLC) whose disease has progressed after: 1 ? alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or ? crizotinib and at least one other ALK TKI Dosing Information The recommended dose is 100mg lorlatinib taken orally once daily. Treatment with lorlatinib
,EasternCooperativeOncologyGroup; EGFR,epidermalgrowthfactorreceptor;IHC,immunohistochemistry;N/A, notapplicable;NSCLC, non–small-cell lungcancer; PD-L1, programmed death ligand 1; PS, performance status; SCC, squamous cell carcinoma; Teff, T effector; TPS, tumor proportion score. Journal of Clinical Oncology 7 Systemic Therapy for Stage IV NSCLC Guideline UpdatePatients with cancers with sensitizing EGFR or ALK alter- ations were excluded from the trial. The study’s primary outcomeswereOSandPFS.OSintheinterventionarmwas (...) Therapy for Stage IV Non–Small-Cell LungCancer Without Driver Alterations ASCO special articles TherapyforStageIVNon–Small-CellLungCancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update Nasser H. Hanna,MD 1 ; Bryan J. Schneider,MD 2 ; Sarah Temin, MSPH 3 ; Sherman Baker Jr, MD 4 ; Julie Brahmer,MD 5 ; Peter M. Ellis, MD, PhD 6 ; Laurie E. Gaspar, MD, MBA 7,8 ; Rami Y. Haddad,MD 9 ; Paul J. Hesketh,MD 10 ; Dharamvir Jain,MD 11 ; Ishmael Jaiyesimi,MD 12 ; David H. Johnson,MD
cancers include a careful history and physical examination at routine intervals, with the inclusion of radiographic imaging and, in select malignancies, serum biomarker evaluation. Unfortunately, two-thirds of patients with lungcancer who relapse present with metastatic incurable disease, and, as yet, there is limited evidence to support the concept that detection and treatment of asymptomatic metastatic recurrences improves outcome due to the concern of lead-time bias. However, patients may present (...) (pT1aN0M0R0), the 5-year survival estimate is 75%-80% and may be as high as 91% in screen-detected early-stage cancers. Given the increased use of lungcancer screening, it is anticipated that a larger number of smaller tumors will be detected and treated with resection or SBRT in the future. It will be a matter of future studies to determine if a less-frequent surveillance regimen is warranted in these patients, with more emphasis on detection of second primariesand less on determining disease recurrence
Guideline Update Guideline Question What systemic therapy treatment options should be offered to patients with stage IV non–small-cell lungcancer (NSCLC) without driver alterations, depending on the subtype of the patient’s cancer? Target Population Patients with stage IV NSCLC without driver alterations in epidermal growth factor receptor ( EGFR ) or anaplastic lymphoma kinase ( ALK ) (with known EGFR and ALK ) status (plus programmed death ligand 1 (PD-L1) tumor proportion score (TPS) test results (...) Therapy for Stage IV Non-Small Cell LungCancer without Driver Alterations Therapy for Stage IV Non–Small-Cell LungCancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.19.03022 Journal of Clinical Oncology - published online before print January 28, 2020 PMID: Therapy for Stage IV Non
Hand-held Fan Airflow Stimulation Relieves Dyspnea in LungCancer Patients. The main symptom of lungcancer is dyspnea which can lead to depression, anxiety, limited independent activities, and decreased quality of life. The purpose of this study was to identify the effect of airflow stimulation from a hand-held fan as nonpharmacological palliative intervention on dyspnea in patients with lung cancer.This study used open, randomized, controlled, crossover trial design involved 21 participants (...) . Diaphragmatic breathing technique was used in control arm.Wilcoxon test result showed that airflow stimulation significantly influenced dyspnea scale (P = 0.003) and respiratory rate (RR) (P = 0.008). Combination of airflow stimulation and diaphragmatic breathing can lower both dyspnea scale and RR significantly (P < 0.0001).This combination can be applied on nonhypoxemic dyspneic lungcancer patients.
Bevacizumab (Zirabev) - colorectal cancer, non-small cell lungcancer, peritoneal cancer, glioblastoma Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity
Thoren ? Volker Vervölgyi Keywords: dacomitinib, carcinoma – non-small-cell lung, benefit assessment, NCT01774721 Extract of dossier assessment A19-39 Version 1.0 Dacomitinib (non-small cell lungcancer) 30 July 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - iii - Table of contents Page List of tables iv List of abbreviations v 2 Benefit assessment 1 2.1 Executive summary of the benefit assessment 1 2.2 Research question 8 2.3 Research question 1: patients with the activating EGFR (...) It was assumed for the present therapeutic indication that the NSCLC patients have stage IIIB to IV disease (staging according to the International Association for the Study of LungCancer [IASLC], Union for International Cancer Control [UICC]), without medical indication for curative resection, radiotherapy or radiochemotherapy. In the present assessment, the following terms are used for the respective populations of the research questions: ? Research question 1: patients with the activating EGFR mutations
High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008 The R2Pulm trial was conducted to evaluate the effect of busulfan-melphalan high-dose chemotherapy with autologous stem-cell rescue (BuMel) without whole-lung irradiation (WLI) on event-free survival (main end point) and overall survival, compared with standard chemotherapy
Atezolizumab (Tecentriq) - metastatic non-squamous non-small cell lungcancer (NSCLC) Published 09 December 2019 1 Statement of advice SMC2254 atezolizumab 1,200mg concentrate for solution for infusion (Tecentriq®) Roche Products Ltd 8 November 2019 ADVICE: in the absence of a submission from the holder of the marketing authorisation atezolizumab (Tecentriq®) is not recommended for use within NHSScotland. Indication under review: In combination with nab-paclitaxel and carboplatin for the first (...) -line treatment of adult patients with metastatic non-squamous non-small cell lungcancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium
. Current/ex-smokers with mild/moderate chronic obstructive pulmonary disease (COPD) were allocated (1:1) to have 5 years surveillance or not. Screened participants provided annual sputum samples for cytology and cytometry, and if abnormal were offered annual LDCT and autofluorescence bronchoscopy (AFB). Those with normal sputum provided annual samples. The primary end-point was the percentage of lungcancers diagnosed at stage I/II (nonsmall cell) or limited disease (small cell).1568 participants were (...) randomised during 2007-2011 from 10 UK centres. 85.2% of those screened provided an adequate baseline sputum sample. There were 42 lungcancers among 785 screened individuals and 36 lungcancers among 783 controls. 54.8% (23 out of 42) of screened individuals versus 45.2% (14 out of 31) of controls with known staging were diagnosed with early-stage disease (one-sided p=0.24). Relative risk was 1.21 (95% CI 0.75-1.95) or 0.82 (95% CI 0.52-1.31) for early-stage or advanced cancers, respectively. Overall
Atezolizumab (Tecentriq) - non-squamous non-small cell lungcancer (NSCLC) 1 Published 11 November 2019 1 SMC2208 atezolizumab 1,200mg concentrate for solution for infusion (Tecentriq®) Roche Products Ltd 04 October 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission considered under (...) the end of life medicine process: atezolizumab (Tecentriq ® ) is not recommended for use within NHSScotland. Indication under review: In combination with bevacizumab, paclitaxel and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous non-small cell lungcancer (NSCLC). In patients with epidermal growth factor receptor (EGFR) mutant or anaplastic lymphoma kinase (ALK)-positive NSCLC, atezolizumab in combination with bevacizumab, paclitaxel and carboplatin
Dacomitinib (Vizimpro) - non-small cell lungcancer (NSCLC) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September
Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lungcancer: systematic review and network meta-analysis. To compare the efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor (EGFR) mutated non-small cell lungcancer (NSCLC).Systematic review and network meta-analysis.PubMed, Embase, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and several